State Street SPDR S&P Biotech ETF
201 hedge funds and large institutions have $2.32B invested in State Street SPDR S&P Biotech ETF in 2016 Q2 according to their latest regulatory filings, with 43 funds opening new positions, 64 increasing their positions, 56 reducing their positions, and 34 closing their positions.
26% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 34
14% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 56
3% more funds holding
Funds holding: 195 → 201 (+6)
1% more capital invested
Capital invested by funds: $2.3B → $2.32B (+$20.7M)
6.86% less ownership
Funds ownership: 119.02% → 112.16% (-6.9%)
39% less call options, than puts
Call options by funds: $539M | Put options by funds: $880M
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
Top Buyers
| 1 |
Citigroup
New York
|
+$149M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
+$87.7M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
+$26.9M |
| 4 |
HI
Honeywell International
Charlotte,
North Carolina
|
+$20.8M |
| 5 |
Rafferty Asset Management
New York
|
+$13.4M |
Top Sellers
| 1 |
Goldman Sachs
New York
|
-$194M |
| 2 |
Morgan Stanley
New York
|
-$145M |
| 3 |
JP Morgan Chase
New York
|
-$41.8M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$33M |
| 5 |
Millennium Management
New York
|
-$20.6M |
XBI Hedge Fund Activity: Q2 2016 in Review
201 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q2 2016, worth a combined $2.32B — up 0.9% from $2.3B a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new XBI positions and 34 closed out — a net gain of 9 holders — while 64 added to existing stakes and 56 trimmed.
The largest buyer was Citigroup, adding an estimated $149M. The largest seller was Goldman Sachs, cutting an estimated $194M.
- 201 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q2 2016, up from 195 in Q1 2016.
- Funds reported $2.32B of State Street SPDR S&P Biotech ETF stock for Q2 2016, up 0.9% quarter-over-quarter.
- 43 funds opened new State Street SPDR S&P Biotech ETF positions in Q2 2016 and 34 closed out, a net change of +9 holders.
- The largest State Street SPDR S&P Biotech ETF buyer in Q2 2016 was Citigroup, an estimated $149M added.
- The largest State Street SPDR S&P Biotech ETF seller in Q2 2016 was Goldman Sachs, an estimated $194M sold.
Based on aggregated 13F filings for Q2 2016.